10日投资提示：宏柏新材股东拟减持不超2.98%股份

Group 1 - The core viewpoint of the article highlights recent corporate actions including shareholder reductions and regulatory warnings from the FDA [1] - Hongbo New Materials plans to reduce its shareholding by no more than 2.98% [1] - Jiahua Intelligent intends to reduce its shareholding by no more than 1% [1] - Huahai Pharmaceutical received a warning letter from the FDA based on an inspection conducted from January 16 to January 24, 2025, regarding its production facility [1] - The warning letter addressed issues related to cleaning management of solid oral production equipment, maintenance of sterile production areas, and the adequacy of parameters for tablet rejection studies [1] - Huahai Pharmaceutical is taking measures to optimize its operations and is maintaining active communication with the FDA to enhance its quality management system [1] - Zhaoziyang, the secretary of the board of directors of Ruifeng High Materials, is under investigation for suspected insider trading [1] - New stock listings and subscription opportunities are mentioned, including the listing of Jiaoda Iron and the subscription for Zhongjin Yizhuang Industrial Park REIT [1]